|
1
|
Schiffman M and Castle PE: The promise of
global cervical-cancer prevention. N Engl J Med. 353:2101–2104.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mandelblatt JS, Lawrence WF, Womack SM,
Jacobson D, Yi B, Hwang YT, Gold K, Barter J and Shah K: Benefits
and costs of using HPV testing to screen for cervical cancer. JAMA.
287:2372–2381. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moody CA and Laimins LA: Human
papillomavirus oncoproteins: pathways to transformation. Nat Rev
Cancer. 10:550–560. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiffman M and Solomon D: Screening and
prevention methods for cervical cancer. JAMA. 302:1809–1810. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sørbye SW, Fismen S, Gutteberg T and
Mortensen ES: Triage of women with minor cervical lesions: data
suggesting a ‘test and treat’ approach for HPV E6/E7 mRNA testing.
PLoS One. 5:e127242010.PubMed/NCBI
|
|
6
|
Small W Jr, Mell LK, Anderson P,
Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L,
Schefter T, Iyer R, Varia M, Winter K and Mundt AJ: Consensus
guidelines for delineation of clinical target volume for
intensity-modulated pelvic radiotherapy in postoperative treatment
of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys.
71:428–434. 2008.
|
|
7
|
Grigsby PW: Radiotherapy for pelvic
recurrence after radical hysterectomy for cervical cancer. Radiat
Med. 23:327–330. 2005.PubMed/NCBI
|
|
8
|
Klopp AH and Eifel PJ: Chemoradiotherapy
for cervical cancer in 2010. Curr Oncol Rep. 13:77–85. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanderup K, Georg D, Pötter R, Kirisits C,
Grau C and Lindegaard JC: Adaptive management of cervical cancer
radiotherapy. Semin Radiat Oncol. 20:121–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bromley SK, Mempel TR and Luster AD:
Orchestrating the orchestrators: chemokines in control of T cell
traffic. Nat Immunol. 9:970–980. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sallusto F and Baggiolini M: Chemokines
and leukocyte traffic. Nat Immunol. 9:949–952. 2008. View Article : Google Scholar
|
|
12
|
Campanella GS, Colvin RA and Luster AD:
CXCL10 can inhibit endothelial cell proliferation independently of
CXCR3. PLoS One. 5:e127002010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Guo S and Stiles JK: The emerging
role of CXCL10 in cancer. Oncol Lett. 2:583–589. 2011.PubMed/NCBI
|
|
14
|
Dufour JH, Dziejman M, Liu MT, Leung JH,
Lane TE and Luster AD: IFN-gamma-inducible protein 10 (IP-10;
CXCL10)-deficient mice reveal a role for IP-10 in effector T cell
generation and trafficking. J Immunol. 168:3195–3204. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zipin-Roitman A, Meshel T, Sagi-Assif O,
Shalmon B, Avivi C, Pfeffer RM, Witz IP and Ben-Baruch A: CXCL10
promotes invasion-related properties in human colorectal carcinoma
cells. Cancer Res. 67:3396–3405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang HM, Yuan J, Cheung P, Chau D, Wong
BW, McManus BM and Yang D: Gamma interferon-inducible protein 10
induces HeLa cell apoptosis through a p53-dependent pathway
initiated by suppression of human papillomavirus type 18 E6 and E7
expression. Mol Cell Biol. 25:6247–6258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frosina G: DNA repair and resistance of
gliomas to chemotherapy and radiotherapy. Mol Cancer Res.
7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mazumder S, Plesca D and Almasan A: A
jekyll and hyde role of cyclin E in the genotoxic stress response:
switching from cell cycle control to apoptosis regulation. Cell
Cycle. 6:1437–1442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawauchi S, Yamamoto Y, Uchida K, Chochi
Y, Kondo T, Oga A and Sasaki K: Significance of cyclin E and p27
expression in malignant ovarian germ cell tumors: correlation with
the cell proliferation activity and clinicopathologic features.
Oncol Rep. 16:1029–1033. 2006.PubMed/NCBI
|
|
21
|
Bhatia B, Malik A, Fernandez A and Kenney
AM: p27(Kip1), a double-edged sword in Shh-mediated
medulloblastoma: Tumor accelerator and suppressor. Cell Cycle.
9:4307–4314. 2010. View Article : Google Scholar : PubMed/NCBI
|
